New Real-World Data Study from BioCryst Shows Orladeyo Reduces HAE Attacks

Biocryst Pharmaceuticals presented results from a new real-world data (RWD) study at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) showing that once-daily Orladeyo (berotralstat) reduces heart attack rates in patients with hereditary angioedema (HAE). This effect was observed regardless of previous prophylactic use and was sustained long-term.

According to Dr. Ryan Arnold, chief medical officer of BioCryst, “These data are particularly exciting because, consistent with our long-term clinical program data, they show that patients on ORLADEYO sustain, and even improve, attack control the longer they are on therapy.”

To read more, click here.

(Source: Yahoo, November 10^th, 2022)